{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:28Z","timestamp":1787019568998,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with relapsed and refractory (R\/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen receptor T-cell (CAR-T) therapy now presenting a curative option for a subset of those patients. However, with the approval of several novel bispecific monoclonal antibody (BsAb) therapies with considerable activity in R\/R aggressive large B-cell lymphomas (LBCL), patients and oncologists will be faced with decisions regarding how to sequence CAR-T and BsAb therapies based on patient- and disease-related factors. In this review, we compare CAR-T and BsAb therapies for R\/R LBCL, highlighting data on the efficacy and toxicity of each treatment paradigm, and provide a roadmap for sequencing these highly effective therapies.<\/jats:p>","DOI":"10.1182\/hematology.2023000438","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:10:58Z","timestamp":1702030258000},"page":"370-381","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas"],"prefix":"10.1182","volume":"2023","author":[{"given":"Ajay","family":"Major","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"2023120815064107100_hem2023000438C1","article-title":"5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1) [published online February 23, 2023]","author":"Neelapu","journal-title":"Blood"},{"issue":"7","key":"2023120815064107100_hem2023000438C2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"2023120815064107100_hem2023000438C3","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2023120815064107100_hem2023000438C4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"26","key":"2023120815064107100_hem2023000438C5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2023120815064107100_hem2023000438C6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"2023120815064107100_hem2023000438C7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"2023120815064107100_hem2023000438C8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large b-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2022-157554","article-title":"Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment","volume":"140","author":"Hutchings","year":"2022","journal-title":"Blood"},{"issue":"10306","key":"2023120815064107100_hem2023000438C10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase \u00bd study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"2023120815064107100_hem2023000438C11","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023120815064107100_hem2023000438C12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023120815064107100_hem2023000438C13","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma [published online April 17, 2023]","author":"Bartlett","journal-title":"Blood Adv"},{"issue":"5","key":"2023120815064107100_hem2023000438C14","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u200a\u00d7\u200aCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023120815064107100_hem2023000438C15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023120815064107100_hem2023000438C16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2023120815064107100_hem2023000438C17","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","article-title":"Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma","volume":"29","author":"Westin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023120815064107100_hem2023000438C18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"2023120815064107100_hem2023000438C19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2023120815064107100_hem2023000438C20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C21","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood-2022-159594","article-title":"Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged &lt;65 and \u226565 years with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and \u22651 prior therapy: subgroup analysis of a phase Ib\/II study","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C22","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin's lymphoma: recommended dose safety\/efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"15, suppl","key":"2023120815064107100_hem2023000438C23","doi-asserted-by":"crossref","first-page":"TPS7569","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7569","article-title":"Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"39","author":"Thieblemont","year":"2021","journal-title":"J Clin Oncol"},{"issue":"27","key":"2023120815064107100_hem2023000438C24","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023120815064107100_hem2023000438C25","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023120815064107100_hem2023000438C26","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2023120815064107100_hem2023000438C27","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2021-149679","article-title":"Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): impact of age and specific organ dysfunction","volume":"138","author":"Locke","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2022-158822","article-title":"Real-world outcomes for patients with relapsed or refractory (R\/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","volume":"140","author":"Landsburg","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023120815064107100_hem2023000438C30","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C31","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2022-163678","article-title":"Real-world effectiveness and economic impact associated with chimeric antigen receptor T-cell therapy among older patients with relapsed\/refractory diffuse large B-cell lymphoma in US","volume":"140","author":"Chihara","year":"2022","journal-title":"Blood"},{"issue":"27","key":"2023120815064107100_hem2023000438C32","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023120815064107100_hem2023000438C33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/hon.113_2630","article-title":"Safety and efficacy of axicabtagene ciloleucel (AXI-CEL) in older patients: results from the US lymphoma CAR-T consortium","volume":"37","author":"Sano","year":"2019","journal-title":"Hematol Oncol"},{"issue":"4","key":"2023120815064107100_hem2023000438C34","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023120815064107100_hem2023000438C35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"2023120815064107100_hem2023000438C36","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2023120815064107100_hem2023000438C37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2023120815064107100_hem2023000438C38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"2023120815064107100_hem2023000438C39","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023120815064107100_hem2023000438C40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023120815064107100_hem2023000438C41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","article-title":"CAR T-Cell Therapy in the older person: indications and risks","volume":"24","author":"Shouse","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2023120815064107100_hem2023000438C42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/aol-22-7","article-title":"Transplant and chimeric antigen receptor T-cell therapies in elderly patients with lymphoma, a narrative review","volume":"6","author":"Greenwell","year":"2022","journal-title":"Ann Lymphoma"},{"key":"2023120815064107100_hem2023000438C43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejca.2022.08.019","article-title":"Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population","volume":"175","author":"Vic","year":"2022","journal-title":"Eur J Cancer"},{"issue":"14","key":"2023120815064107100_hem2023000438C44","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2023120815064107100_hem2023000438C45","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","article-title":"Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults","volume":"3","author":"Derman","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2023120815064107100_hem2023000438C46","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"2023120815064107100_hem2023000438C47","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023120815064107100_hem2023000438C48","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"23","key":"2023120815064107100_hem2023000438C49","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023120815064107100_hem2023000438C50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023120815064107100_hem2023000438C51","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2022-162594","article-title":"CAR T-cell therapy remain effective in patients with relapse\/refractory B-cell Non-Hodgkin lymphoma after bispecific antibodies exposure: results of a Lysa study based on the DESCAR-T registry","volume":"140","author":"Crochet","year":"2022","journal-title":"Blood"},{"issue":"suppl 2","key":"2023120815064107100_hem2023000438C52","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hon.3166_OT19","article-title":"SWOG 2114: a randomized phase II trial of consolidation therapy following CD19 CAR T-cell treatment for relapsed\/refractory large B-cell or grade IIIB follicular lymphoma","volume":"41","author":"Hess","year":"2023","journal-title":"Hematol Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/370\/2175892\/370major.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/370\/2175892\/370major.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:11:23Z","timestamp":1702030283000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/370\/506455\/Selection-of-bispecific-antibody-therapies-or-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000438","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}